Business description: Neuronetics, Inc.

Neuronetics, Inc. a vertically integrated, commercial stage, medical technology and healthcare company. The Company’s NeuroStar Advanced Therapy (NeuroStar Therapy) is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions. In addition to selling the NeuroStar Advanced Therapy System (NeuroStar System) and associated treatment sessions to customers, it operates Greenbrook treatment centers across the United States, offering NeuroStar Therapy for the treatment of major depressive disorder (MDD) and other mental health disorders. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. MDD is a recurrent disease and follows a fluctuating course over an individual’s lifetime. The Company provides more than 7.1 million treatments to over 1,95,000 patients.

Number of employees: 658

Sales by Activity: Neuronetics, Inc.

Fiscal Period: December 2021 (USD) 2022 (USD) 2023 (USD) 2024 (USD) 2025 (USD)

Clinic Services Market

- - - - 86.98M

Medical Device

- - - - 62.18M

Surgical & Medical Equipment

55.31M 65.21M 71.35M 74.89M -

Geographical breakdown of sales: Neuronetics, Inc.

Fiscal Period: December 2021 (USD) 2022 (USD) 2023 (USD) 2024 (USD) 2025 (USD)

United States

53.45M 63.41M 69.34M 72.49M 146M

International

1.86M 1.8M 2.01M 2.4M 3.11M

Executive Committee: Neuronetics, Inc.

Manager TitleAgeSince
Chief Executive Officer 63 22/03/2026
Director of Finance/CFO - 04/05/2026
Chief Operating Officer 69 18/06/2025
Sales & Marketing - 31/05/2026
Sales & Marketing - 30/04/2023

Composition of the Board of Directors: Neuronetics, Inc.

Director TitleAgeSince
Director/Board Member 67 30/06/2017
Director/Board Member 65 30/09/2019
Chairman 71 26/05/2021
Director/Board Member 49 01/08/2021
Director/Board Member 49 09/12/2024
Director/Board Member 56 09/12/2024
Director/Board Member 63 22/03/2026

Shareholders: Neuronetics, Inc.

NameStocks%Valuation
Madryn Asset Management LP
31.47 %
20,809,561 31.47 % 27 M $
16.01 %
10,588,988 16.01 % 14 M $
Parian Ultreia LP
7.327 %
4,844,908 7.327 % 6 M $
UBS Financial Services, Inc.
4.296 %
2,840,591 4.296 % 4 M $
Balyasny Asset Management LP
4.149 %
2,743,768 4.149 % 4 M $

Company details: Neuronetics, Inc.

Neuronetics, Inc.

3222 Phoenixville Pike

19355, Malvern

+877 600 7555

http://www.neurostar.com
address Neuronetics, Inc.(STIM)

Other Advanced Medical Equipment & Technology

Change 5-day change 1-year change 3-year change Capi.($)
-6.93%+6.21%-51.55%-8.74% 131M
-0.53%-1.99%+29.27%-6.89% 195B
-10.99%-10.07%-4.82%-30.04% 126B
-0.88%-7.76%-32.17%+3.98% 124B
-1.33%+1.31%-58.38%-18.75% 64.2B
-0.53%-6.15%+10.44%-8.66% 48.68B
-0.55%-1.01%-24.69%-32.86% 43.83B
+2.00%-1.73%+18.58%+4.11% 37.52B
+2.80%-2.35%+30.49%+27.30% 36.09B
-1.41%+1.45%-25.00%-10.98% 28.24B
Average -1.39%-2.21%-10.78%-8.15% 70.3B
Weighted average by Cap. -1.67%-3.86%-3.04%-9.76%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.880USD
Average target price
4.500USD
Spread / Average Target
+139.36%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. STIM Stock
  4. Company Neuronetics, Inc.